- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
--------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO
SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): MAY 5, 2000
--------------------
GENOME THERAPEUTICS CORP.
(Exact name of registrant as specified in its charter)
MASSACHUSETTS 0-10824 04-2297484
(State or other jurisdiction (Commission File Number) (I.R.S. Employer
of incorporation) Identification Number)
100 BEAVER STREET
WALTHAM, MASSACHUSETTS 02453
(Address, of principal executive offices, including zip code)
(781) 398-2300
(Registrant's Telephone number including area code)
--------------------
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
PAGE 1 OF 4 PAGES.
Item 5. OTHER EVENTS
On May 2, 2000, Genome Therapeutics Corp. issued a press release
announcing an extension to its human genomics alliance with Schering-Plough
Corporation to discover new therapeutics for treating asthma. The extension
will carry the research portion of the alliance at least through December
2001. A copy of this press release is attached to this Current Report on Form
8-K as Exhibit 99.1.
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
GENOME THERAPEUTICS CORP.
By /s/ Robert J. Hennessey
--------------------------------
Title: Chairman of the Board and
Chief Executive Officer
Date: May 5, 2000
-3-
EXHIBIT INDEX
99.1 Press Release dated May 2, 2000
-4-